Clinical Pharmacology & Human ADME Studies: A Roadmap to Market - London, UK

Join us for an enlightening scientific seminar and lunch.

In today’s drug development landscape, efficient completion of the clinical pharmacology package is essential to ensure successful NDA submission. However, the nature of these trials, and especially human ADME studies, often require a series of specialist vendors to support program design and execution. At Quotient Sciences, we specialize in taking the strain off our customers by integrating scientific expertise built over hundreds of clinical projects, with end-to-end services for these complex programs.

In this seminar, we’ll discuss 15 years of delivering human ADME data through our Synthesis-to-Clinic^® platform, which relieves the of these programs by placing all steps from radiosynthesis, drug product manufacture, clinical delivery, mass balance, and metabolite profiling; often under a single contract. Whether conducting human ADME for New Drug Applications (NDA) or running in parallel with Phase II Proof of Concept (POC) studies, our Synthesis-to-Clinic^® integrated ADME studies are enabled by applying Translational Pharmaceutics^®.

Quotient Sciences' scientific experts will also explore the construct of the drug-drug interaction (DDI) package from initial drug assessments, and in-silico evaluations, through to design of “multi-interaction” studies and DDI cocktail studies.

Through real-world case studies and expert insights, you will discover how we become an extension of your team, delivering not just services, but real expertise for the benefits of your development program.

*We reserve the right, at our sole discretion, to deny registration or remove any individual who is not a confirmed current or potential client/partner of Quotient Sciences.